BioGaia AB Launches Subsidiary Company, BioGaia New Sciences AB

Published: 2025-07-16 05:05:21 ET BIOG B.ST

Published on 07/16/2025 at 05:05 - Modified on 07/17/2025 at 08:17

BioGaia announced the launch of a subsidiary company, BioGaia New Sciences AB, dedicated to exploring opportunities in microbiome friendly and biotics-containing products beyond BioGaia's current core focus areas: gut health, immune health, and oral health. The first area for the new company will be skin health, a natural next step, given the parallels between skin and gut microbiomes. The skin microbiome, much like the gut microbiome, plays a vital role in overall health.

In early life, both develop in similar ways as they are shaped by birth, environment and nutrition, making the skin a promising and exciting next step for microbiome-friendly solutions. The global skin microbiome market is entering a high-growth phase, with a valuation of USD 1.03 billion in 2024 and expected to reach USD 2.86 billion by 2032, driven by a projected CAGR of 13.7% from 2025 onwards. This explosive growth reflects increasing consumer focus on science-backed skincare and expanding innovation in microbiome-specific formulation trends that align strongly with BioGaia New Sciences's strategy.

To lead this new venture, BioGaia New Sciences has appointed Maik Lepatey as CEO. Maik brings extensive experience with a long and successful background in the skin care and beauty industry, including at L'Oreal. Maik joins and will lead an expert team already on board in the areas of skin health, dermatology, skin care product development, and consumer health.

BioGaia New Sciences builds on BioGaia's vision to develop science-based, clinically relevant products, starting with BioGaia Aldermis, a probiotic ointment for dry and sensitive skin in infants and children currently available in North America. In addition, BioGaia New Sciences have recently acquired new product formulations including microbiome-friendly skin care products for infants and children. This new venture does not materially impact financial results.